GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tego Science Inc (XKRX:191420) » Definitions » Debt-to-Equity

Tego Science (XKRX:191420) Debt-to-Equity : 0.03 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Tego Science Debt-to-Equity?

Tego Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,391 Mil. Tego Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩137 Mil. Tego Science's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩45,835 Mil. Tego Science's debt to equity for the quarter that ended in Mar. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tego Science's Debt-to-Equity or its related term are showing as below:

XKRX:191420' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.52
Current: 0.03

During the past 11 years, the highest Debt-to-Equity Ratio of Tego Science was 0.52. The lowest was 0.00. And the median was 0.02.

XKRX:191420's Debt-to-Equity is ranked better than
88.77% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.295 vs XKRX:191420: 0.03

Tego Science Debt-to-Equity Historical Data

The historical data trend for Tego Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tego Science Debt-to-Equity Chart

Tego Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.02 0.03

Tego Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

Competitive Comparison of Tego Science's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tego Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tego Science's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tego Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tego Science's Debt-to-Equity falls into.



Tego Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tego Science's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Tego Science's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tego Science  (XKRX:191420) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Tego Science Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tego Science's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tego Science (XKRX:191420) Business Description

Traded in Other Exchanges
N/A
Address
8, Maagok central, gangseo-gu, Seoul, KOR
Tego Science Inc is a biotech company that researches and develops regenerative medicine. It is engaged in the production of epidermis and cornea wound healing solution. Its products include Holoderm, SkinBank, Kaloderm, and Neoderm. It also provides testing services.

Tego Science (XKRX:191420) Headlines

No Headlines